ArticleBMC microbiology2026
Impact of gut microbiota on atypical endometrial hyperplasia and endometrial cancer: a comprehensive analysis of microbial composition and metabolomic profiling.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundEndometrial cancer (EC) is one of the most common malignant tumors in women, and in recent years, the role of gut microbiota in tumorigenesis has gradually gained attention. Previous studies have shown that the gut microbiome is closely related to the occurrence of various cancers, but the specific mechanisms through which gut microbiota contribute to the development of endometrial cancer (EC) remain unclear. This study aims to analyze the gut microbiome characteristics of atypical endometrial hyperplasia (AEH) and EC, and to explore key gut microbial species and metabolites, providing evidence for the etiological research and early screening of EC and AEH.
methodsThis study selected 24 AEH or EC patients from the Gynecology Department of Gansu Provincial Maternity and Child Care Hospital between February 2023 and October 2023. The patients were divided into the AEH group (n=7) and the EC group (n=17), with 24 healthy women selected as a control group. Fecal and serum samples were collected, and 16S rRNA gene sequencing was performed using the Illumina MiSeq platform. Serum metabolomics analysis was conducted using LC-MS technology. Spearman correlation analysis was used to explore the associations between gut microbiota and metabolites, and potential gut microbial biomarkers were evaluated using ROC analysis.
resultsThe study found that as AEH progressed to EC, significant changes occurred in the composition of the gut microbiota, particularly in Klebsiella, whose abundance increased from 0.264% in the control group to 0.809% in the AEH group and 6.092% in the EC group, with significant differences (P<0.001, FDR=0.026). LEfSe analysis identified Megamonas, Klebsiella, Escherichia, and Akkermansia as potential biomarkers. ROC analysis showed that the AUCs of Megamonas/Klebsiella for EC were 0.864/0.838, and the AUCs of Escherichia/Akkermansia for AEH were 0.744/0.920. Metabolomics analysis revealed significant enrichment of glycerophospholipid metabolism in both the EC and AEH groups, with significant differences in lipid metabolism in the EC group. Correlation analysis indicated significant positive correlations between Enterococcus and hypoxanthine, inosine in the EC group (r=0.686, 0.637, P<0.05).
conclusionThis study reveals the dynamic changes in the gut microbiome during the development of endometrial lesions, especially the increasing abundance of Klebsiella as AEH progresses to EC, suggesting that it may play a key role in the occurrence and progression of EC. Furthermore, significant changes in lipid metabolism further support the role of gut microbiota in regulating lipid metabolism in EC pathogenesis. This study provides new insights into the role of gut microbiota in endometrial cancer and offers a theoretical basis for early diagnosis and personalized treatment strategies based on gut microbiota.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.